Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta cell antigens (including insulin) immunotherapy
- Development stage
- Unknown
- Lead developer
- Diamyd Medical
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intralymphatic, Subcutaneous, Intranasal
01
Overview
This antigen-specific immunotherapy is being developed by Diamyd Medical, with Johnny Ludvigsson as a key investigator and sponsor, for the treatment and prevention of Type 1 Diabetes (T1D) in patients carrying the HLA DR4-DQ8 haplotype. Unlike the company's lead candidate, which targets the GAD65 antigen in HLA DR3-DQ2 positive individuals, this program utilizes a broader set of beta cell antigens, specifically including insulin, to induce immune tolerance. The therapy aims to reprogram the immune system to prevent the autoimmune destruction of pancreatic beta cells, thereby preserving residual insulin production. It is currently in Phase 1 clinical development and is intended for patients across Stages 1, 2, and 3 of the disease who possess the specific genetic marker.
- Other names
- Additional beta cell antigens (including insulin)insulin-based antigen-specific immunotherapy
Beyond the preview
Go deeper on beta cell antigens (including insulin) immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta cell antigens (including insulin) immunotherapy.